Appendix 3. Supplementary Tables

Percentage of Women (95% Confidence Interval) Achieving Geometric Mean Concentrations of ≥ 0.5, ≥ 1, ≥ 2, ≥ 3, ≥ 5 and ≥ 8 Micrograms/mL at Each Tested Time Point, Split by Baseline Antibody Status for Serotype Ia

	GBS < LLQ	GBS ≥ LLQ	Placebo < LLQ	Placebo ≥ LLQ
Baseline				
≥0.5 µg/mL	0% (0%–9%)	100% (69%–100%)	0% (0%–14%)	91% (59%–100%)
≥1 µg/mL	0% (0%–9%)	70% (35%–93%)	0% (0%–14%)	73% (39%–94%)
≥2 µg/mL	0% (0%–9%)	50% (19%–81%)	0% (0%–14%)	45% (17%–77%)
≥3 µg/mL	0% (0%–9%)	50% (19%–81%)	0% (0%–14%)	36% (11%–69%)
≥5 µg/mL	0% (0%–9%)	40% (12%–74%)	0% (0%–14%)	27% (6%–61%)
≥8 µg/mL	0% (0%–9%)	10% (0%–45%)	0% (0%–14%)	18% (2%–52%)
Day 31				
≥0.5 µg/mL	63% (46%–77%)	100% (66%–100%)	5% (0%–23%)	90% (55%–100%)
≥1 µg/mL	55% (38%–71%)	100% (66%–100%)	5% (0%–23%)	80% (44%–97%)
≥2 µg/mL	38% (23%–54%)	100% (66%–100%)	5% (0%–23%)	50% (19%–81%)
≥3 µg/mL	38% (23%–54%)	100% (66%–100%)	5% (0%–23%)	40% (12%–74%)
≥5 µg/mL	35% (21%–52%)	100% (66%–100%)	5% (0%–23%)	30% (7%–65%)
≥8 µg/mL	25% (13%–41%)	100% (66%–100%)	5% (0%–23%)	20% (3%–56%)
Delivery				
≥0.5 µg/mL	80% (65%–91%)	100% (69%–100%)	4% (0%–21%)	91% (59%–100%)
≥1 µg/mL	56% (40%–72%)	100% (69%–100%)	4% (0%–21%)	73% (39%–94%)
≥2 µg/mL	49% (33%–65%)	100% (69%–100%)	4% (0%–21%)	45% (17%–77%)
≥3 µg/mL	44% (28%–60%)	100% (69%–100%)	4% (0%–21%)	36% (11%–69%)
≥5 µg/mL	34% (20%–51%)	100% (69%–100%)	4% (0%–21%)	18% (2%–52%)
≥8 µg/mL	27% (14%–43%)	100% (69%–100%)	4% (0%–21%)	9% (0%–41%)
Day 91 postpartum				
≥0.5 µg/mL	89% (74%–97%)	100% (63%–100%)	9% (1%–28%)	100% (72%–100%)
≥1 µg/mL	67% (49%–81%)	100% (63%–100%)	4% (0%–22%)	91% (59%–100%)
≥2 µg/mL	50% (33%–67%)	100% (63%–100%)	4% (0%–22%)	73% (39%–94%)
≥3 µg/mL	44% (28%–62%)	100% (63%–100%)	4% (0%–22%)	55% (23%–83%)
≥5 µg/mL	42% (26%–59%)	100% (63%–100%)	4% (0%–22%)	36% (11%–69%)
≥8 µg/mL	28% (14%–45%)	100% (63%–100%)	4% (0%–22%)	27% (6%–61%)

Baseline antibody status is based on whether geometric mean concentrations were above or below the lower limit of quantification (LLQ), i.e. the lowest detectable antibody concentration in the assay.

Donders GGG, et al. Maternal immunization with an investigational trivalent group B streptoccocal vaccine: a randomized phase II study. Obstet Gynecol 2016;127.

Percentage of Women (95% Confidence Interval) Achieving Geometric Mean Concentrations of ≥ 0.1, ≥ 0.2, ≥ 0.5, ≥ 1, ≥ 2, ≥ 3, ≥ 5 and ≥ 8 Micrograms/mL at Each Tested Time Point, Split by Baseline Antibody Status for Serotype Ib

	GBS < LLQ	GBS ≥ LLQ	Placebo < LLQ	Placebo ≥ LLQ
Baseline				
≥0.1 µg/mL	0% (0%–13%)	100% (86%–100%)	0% (0%–16%)	100% (75%–100%)
≥0.2 µg/mL	0% (0%–13%)	75% (53%–90%)	0% (0%–16%)	62% (32%–86%)
≥0.5 µg/mL	0% (0%–13%)	33% (16%–55%)	0% (0%–16%)	38% (14%–68%)
≥1 µg/mL	0% (0%–13%)	25% (10%–47%)	0% (0%–16%)	15% (2%–45%)
≥2 µg/mL	0% (0%–13%)	21% (7%–42%)	0% (0%–16%)	0% (0%–25%)
≥3 µg/mL	0% (0%–13%)	13% (3%–32%)	0% (0%–16%)	0% (0%–25%)
≥5 µg/mL	0% (0%–13%)	8% (1%–27%)	0% (0%–16%)	0% (0%–25%)
≥8 µg/mL	0% (0%–13%)	4% (0%–21%)	0% (0%–16%)	0% (0%–25%)
Day 31				
≥0.1 µg/mL	77% (56%–91%)	91% (71%–99%)	15% (3%–38%)	60% (26%–88%)
≥0.2 µg/mL	73% (52%–88%)	91% (71%–99%)	10% (1%–32%)	60% (26%–88%)
≥0.5 µg/mL	31% (14%–52%)	82% (60%–95%)	5% (0%–25%)	40% (12%–74%)
≥1 µg/mL	23% (9%–44%)	68% (45%–86%)	5% (0%–25%)	10% (0%–45%)
≥2 µg/mL	12% (2%–30%)	68% (45%–86%)	5% (0%–25%)	0% (0%–31%)
≥3 µg/mL	12% (2%–30%)	68% (45%–86%)	5% (0%–25%)	0% (0%–31%)
≥5 µg/mL	12% (2%–30%)	68% (45%–86%)	5% (0%–25%)	0% (0%–31%)
≥8 µg/mL	8% (1%–25%)	64% (41%–83%)	5% (0%–25%)	0% (0%–31%)
Delivery				
≥0.1 µg/mL	85% (65%–96%)	96% (79%–100%)	19% (5%–42%)	77% (46%–95%)
≥0.2 µg/mL	85% (65%–96%)	96% (79%–100%)	14% (3%–36%)	54% (25%–81%)
≥0.5 µg/mL	62% (41%–80%)	88% (68%–97%)	5% (0%–24%)	23% (5%–54%)
≥1 µg/mL	31% (14%–52%)	75% (53%–90%)	5% (0%–24%)	8% (0%–36%)
≥2 µg/mL	15% (4%–35%)	71% (49%–87%)	5% (0%–24%)	0% (0%–25%)
≥3 µg/mL	12% (2%–30%)	71% (49%–87%)	5% (0%–24%)	0% (0%–25%)
≥5 µg/mL	12% (2%–30%)	71% (49%–87%)	5% (0%–24%)	0% (0%–25%)
≥8 µg/mL	4% (0.1%–20%)	67% (45%–84%)	5% (0%–24%)	0% (0%–25%)
Day 91 post–partum				
≥0.1 µg/mL	100% (86%–100%)	100% (83%–100%)	37% (16%–62%)	92% (64%–100%)
≥0.2 µg/mL	96% (79%–100%)	100% (83%–100%)	11% (1%–33%)	62% (32%–86%)
≥0.5 µg/mL	71% (49%–87%)	100% (83%–100%)	5% (0%–26%)	46% (19%–75%)
≥1 µg/mL	54% (33%–74%)	90% (68%–99%)	5% (0%–26%)	15% (2%–45%)
≥2 µg/mL	21% (7%–42%)	75% (51%–91%)	5% (0%–26%)	0% (0%–25%)
≥3 µg/mL	21% (7%–42%)	75% (51%–91%)	5% (0%–26%)	0% (0%–25%)
≥5 µg/mL	17% (5%–37%)	65% (41%–85%)	5% (0%–26%)	0% (0%–25%)
≥8 µg/mL	8% (1%–27%)	65% (41%–85%)	5% (0%–26%)	0% (0%–25%)

Baseline antibody status is based on whether GMCs were above or below the lower limit of quantification (LLQ), i.e. the lowest detectable antibody concentration in the assay.

Donders GGG, et al. Maternal immunization with an investigational trivalent group B streptoccocal vaccine: a randomized phase II study. Obstet Gynecol 2016;127.

The authors provided this information as a supplement to their article.

Percentage of Women (95% Confidence Interval) Achieving Geometric Mean Concentrations of ≥ 0.1, ≥ 0.2, ≥ 0.5, ≥ 1, ≥ 2, ≥ 3, ≥ 5 and ≥ 8 Micrograms/mL at Each Tested Time Point, Split by Baseline Antibody Status for Serotype III

	GBS < LLQ	GBS ≥ LLQ	Placebo < LLQ	Placebo ≥ LLQ
Baseline				
≥0.1 µg/mL	0% (0%–11%)	100% (83%–100%)	0% (0%–14%)	100% (72%–100%)
≥0.2 µg/mL	0% (0%–11%)	70% (46%–88%)	0% (0%–14%)	(82% (48%–98%)
≥0.5 µg/mL	0% (0%–11%)	50% (27%–73%)	0% (0%–14%)	45% (17%–77%)
≥1 µg/mL	0% (0%–11%)	35% (15%–59%)	0% (0%–14%)	27% (6%–61%)
≥2 µg/mL	0% (0%–11%)	20% (6%–44%)	0% (0%–14%)	18% (2%–52%)
≥3 µg/mL	0% (0%–11%)	10% (1%–32%)	0% (0%–14%)	18% (2%–52%)
≥5 µg/mL	0% (0%–11%)	0% (0%–17%)	0% (0%–14%)	9% (0%–41%)
≥8 µg/mL	0% (0%–11%)	0% (0%–17%)	0% (0%–14%)	9% (0%–41%)
Day 31				
≥0.1 µg/mL	67% (47%–83%)	100% (82%–100%)	5% (0%–23%)	90% (55%–100%)
≥0.2 µg/mL	57% (37%–75%)	95% (74%–100%)	5% (0%–23%)	70% (35%–93%)
≥0.5 µg/mL	43% (25%–63%)	95% (74%–100%)	5% (0%–23%)	60% (26%–88%)
≥1 µg/mL	20% (8%–39%)	84% (60%–97%)	0% (0%–15%)	40% (12%–74%)
≥2 µg/mL	13% (4%–31%)	79% (54%–94%)	0% (0%–15%)	20% (3%–56%)
≥3 µg/mL	10% (2%–27%)	79% (54%–94%)	0% (0%–15%)	20% (3%–56%)
≥5 µg/mL	7% (1%–22%)	79% (54%–94%)	0% (0%–15%)	20% (3%–56%)
≥8 µg/mL	7% (1%–22%)	79% (54%–94%)	0% (0%–15%)	10% (0%–45%)
Delivery				
≥0.1 µg/mL	81% (63%–93%)	100% (83%–100%)	4% (0%–21%)	82% (48%–98%)
≥0.2 µg/mL	65% (45%–81%)	100% (83%–100%)	4% (0%–21%)	73% (39%–94%)
≥0.5 µg/mL	52% (33%–70%)	95% (75%–100%)	4% (0%–21%)	64% (31%–89%)
≥1 µg/mL	35% (19%–55%)	95% (75%–100%)	0% (0%–14%)	45% (17%–77%)
≥2 µg/mL	26% (12%–45%)	80% (56%–94%)	0% (0%–14%)	27% (6%–61%)
≥3 µg/mL	19% (7%–37%)	80% (56%–94%)	0% (0%–14%)	27% (6%–61%)
≥5 µg/mL	10% (2%–26%)	80% (56%–94%)	0% (0%–14%)	18% (2%–52%)
≥8 µg/mL	6% (1%–21%)	80% (56%–94%)	0% (0%–14%)	9% (0%–41%)
Day 91 postpartum				
≥0.1 µg/mL	85% (65%–96%)	100% (81%–100%)	0% (0%–14%)	90% (55%–100%)
≥0.2 µg/mL	81% (61%–93%)	100% (81%–100%)	0% (0%–14%)	80% (44%–97%)
≥0.5 µg/mL	69% (48%–86%)	100% (81%–100%)	0% (0%–14%)	70% (35%–93%)
≥1 µg/mL	46% (27%–67%)	94% (73%–100%)	0% (0%–14%)	50% (19%–81%)
≥2 µg/mL	23% (9%–44%)	94% (73%–100%)	0% (0%–14%)	30% (7%–65%)
≥3 µg/mL	23% (9%–44%)	89% (65%–99%)	0% (0%–14%)	30% (7%–65%)
≥5 µg/mL	12% (2%–30%)	89% (65%–99%)	0% (0%–14%)	30% (7%–65%)
≥8 µg/mL	8% (1%–25%)	78% (52%–94%)	0% (0%–14%)	30% (7%–65%)

Baseline antibody status is based on whether GMCs were above or below the lower limit of quantification (LLQ), i.e. the lowest detectable antibody concentration in the assay.

Donders GGG, et al. Maternal immunization with an investigational trivalent group B streptoccocal vaccine: a randomized phase II study. Obstet Gynecol 2016;127.

The authors provided this information as a supplement to their article.

